Purpose: The association between neurodegenerative diseases and transfusion remains to be investigated.
INTRODUCTION
Anemia, defined as hemoglobin concentration <12 g/dl in women and <13 g/dl in men according to World Health Organization (WHO), is a prevalent condition worldwide (1) . The burden of anemia is high, an is estimated to effect between 27% to 32.9% of the world population (2, 3) . Anemia is associated with increasing mortality and morbidity (4) . In addition to correct underlying diseases, transfusion is a frequent clinical procedure carried out in patients with anemia (5) (6) (7) (8) . However, transfusion itself is also related to adverse events and complications (9, 10) . Iron overload is one of the inevitable and notorious complications of transfusion, especially in transfusion-dependent patients (11, 12) . Clinical consequences of deregulated iron metabolism and iron overload has previously been reported including hemochromatosis, insulin resistance, peripheral inflammation, cirrhosis, heart failure, and decreased survival benefits (13) (14) (15) (16) (17) .
Recently, decreased serum iron levels have been reported to be causally associated with an increased risk of developing Parkinson's disease (PD) (18) . Abnormal deposits of iron has been observed to pathologically accumulate in the substantia nigra in PD and in the cortex in AD (19) . Lei et al. have also showed that Tau deficiency could induce parkinsonism with dementia by impairing Amyloid precursor protein-mediated iron exports (20) . Duce et al. have found that iron-export ferroxidase activity of the β-amyloid precursor protein undergoes interference and inhibition in AD (21) . The above studies clearly demonstrate that perturbations in iron homeostasis and ferroptotic signaling are tightly associated with the development of neurodegeneration (22) . Furthermore, inflammation can be induced during blood transfusion (23) and has also been reported to be involved in the pathogenesis of neurodegeneration (24) .
Pathogenesis of neurodegeneration also involves misfolding protein aggregation and prorogation through anatomical connections of peripheral neurons (25, 26) . Given the evidence that peripheral inoculation of the misfolded proteins can induce the aggregation of aberrant proteins in mice models and vascular inflammation is associated with dementia (27) (28) (29) (30) , the horizontal transmissibility of neurodegenerative diseases might therefore be possible (31, 32) .
Edgren et al. however, reported that AD and PD cannot be transmitted through blood transfusions with blood originating from donors with misfolded proteins (33) . Whether transfusion is associated with an increased risk of neurodegeneration and dementia remains unknown and called for a nationwide longitudinal cohort study. In this study, we analyzed the association between blood transfusions and the risk of dementia, using data from the National Health Insurance Research Database (NHIRD), which contains claims data of most Taiwanese citizens (> 99% coverage rate) and thus provides valuable information for epidemiological investigations.
METHODS

Data Source
The Taiwan National Health Insurance (NHI) program was implemented in March 1995 and covers approximately 99% of Taiwanese residents (34) . This retrospective population-based cohort study was conducted using data from the NHIRD for the period from 2000 to 2011. The details of the database and the program are provided in previous studies (35) .
Sampled Patients
In this study, we included patients aged ≥20 years who underwent a blood transfusion from 1 January 2000, to 31 December 2011. A blood transfusion was defined as a transfusion of packed red blood cells (RBCs), washed RBCs, frozen deglycerolized RBCs, leukocyte-poor RBCs, platelet concentrate, white blood cells (WBC) concentrate, plateletpheresis, WBCphresis, fresh frozen plasma, frozen plasma, cryoprecipitate, whole blood, and reduced leukocytesplatelets. The date of the blood transfusion was used as the index date. Patients with missing data on their date of birth and sex and those with preexisting dementia (ICD-9-CM codes 290, 331, 294.0, or 294.1) or AD (ICD-9-CM codes 290.1 and 331.0), were excluded. Further, to investigate the long-term effect of transfusion, we delayed the start of follow-ups for dementia by 2 years. Thus, persons with any dementia or AD diagnosed within 2 years after the index date were also excluded.
Every patient who underwent a blood transfusion was propensity score-matched to one randomly selected insurant without any history of blood transfusion, dementia, or AD at baseline. A logistic regression model was used to calculate propensity scores for patients in need of blood transfusion as a function of the background variables including age, sex, year of the index date, urbanization level, occupation, frequency of brain CT/MRI/per year, frequency of psychiatric outpatient visits/per year, and comorbidities. The comorbidities included in this study were diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM code 401 to 405), hyperlipidemia (ICD-9-CM code 272), anxiety (ICD-9-CM code 300.00), depression (ICD-9-CM codes 296.2, 296.3, 300.4, and 311), obesity (ICD-9-CM code 278), bipolar disorder (ICD-9-CM code 296), schizophrenia (ICD-9-CM code 295), head injury (ICD-9-CM codes 800-804, 850-854, and 959.01), injury and poisoning (ICD-9-CM codes 800-999; excluding 800-804, 850-854, and 910-919), posttraumatic stress disorder (ICD-9-CM code 309.81), iron deficiency anemia (ICD-9-CM code 280.9), stroke (ICD-9-CM codes 430-438), and chronic kidney disease (CKD) and endstage renal disease (ICD-9-CM code 585), GI bleeding (ICD-9-CM codes 530-535, 562.12, 562.13, 569.3, 569.85, 578, 455.2, 455.5, 455.8), and surgery (ICD-9-CM procedure codes 01-99). The medications included in this study were benzodiazepine (BZD), non-BZD, and antipsychotics; and the year of the index date listed in Table 1 . The non-BZD included Zopiclone, Zolpidem hemitartrate, Zolpidem tartrate, and Zaleplon. Patients who had a blood transfusion were matched (1:1 ratio) with those who did not have a blood transfusion according to their propensity score through the nearest neighbor matching, initially to the eighth digit and then as required to the first digit. Therefore, matches were first made within a caliper width of 0.0000001, and then the caliper width was increased for unmatched cases to 0.1. We reconsidered the matching criteria and performed a rematch (greedy algorithm). The mean and median propensity scores were compared between the two cohorts.
Outcome
The primary outcome of this study was a diagnosis of dementia (ICD-9-CM codes 290, 331, 294.0, or 294.1) and AD (ICD-9-CM codes 290.1 and 331.0). Each study patient was followed up with until the primary outcome was diagnosed or were censored because of death, withdrawal from the NHI program, or if after 31 December 2011.
Statistical Analysis
The standard mean difference was used to examine the difference in categorical variables and continuous variables between the blood transfusion and matched cohorts. The standard mean difference value was 0.1 or less, which indicated a negligible mean difference between the blood transfusion and matched cohorts. The Kaplan-Meier method was used to estimate the cumulative incidence of subsequent dementia in the blood transfusion and matched cohorts, and significant differences were determined using the log-rank test. We calculated the incidence density rate of dementia according to different risk factors in analyses stratified by age, sex, urbanization level, occupation, comorbidities, and medication. Univariable and multivariable Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the association between blood transfusions and the risks of dementia or AD. The multivariable models were simultaneously adjusted for age, sex, urbanization level, occupation, frequency of brain CT/MRI/per year, and frequency of Psychiatric OPD visit/per year, and comorbidities of diabetes, hypertension, hyperlipidemia, anxiety, depression, obesity, bipolar disorder, schizophrenia, head injury, injury and poisoning, post-traumatic stress disorder, iron deficiency anemia, stroke, CKD and ESRD, GI bleeding, surgery, and medication of benzodiazepine, non-BZD, and anti-psychotic medications. A further analysis was performed to estimate the risk of dementia among patients receiving different types of blood transfusions. All statistical analyses were performed using SAS version 9.4 statistical software (SAS Institute, Inc., Cary, N.C., USA). The significance level for all analyses was set to a p value of 0.05.
RESULTS
Demographic Characteristics, Comorbidities and Medications of Patients With Blood Transfusion and the Matched Cohort
A total of 63,813 patients were included in the blood transfusion cohort and 63,813 persons in the matched cohort, with similar distributions for age, sex, urbanization level, frequency of brain CT/MRI/per year, frequency of psychiatric outpatient visit/per year, occupation, comorbidities, and medication ( Table 1) . The median follow-up period was 3.86 ± 3.52 years in the study cohort and 5.49 ± 3.34 years in the matched cohort. In both cohorts, more than half of the patients were aged <65 years (59.6% vs 60.6%). The mean ages of the blood transfusion and matched cohorts at index date were 58.4 years (SD = 17.1) and 58. 
Incidence Densities and Cox Model Analysis of Risk Factors Affecting Dementia Development
The overall incidence density rates of dementia were 5.50 and 7.73 per 1000 person-years in the matched and blood transfusion cohorts, respectively ( The overall incidence density rates of AD were 0.68 and 0.77 per 1000 person-years in the matched and blood transfusion cohorts, respectively ( Table 3) . Compared with the matched cohort, the HR of AD was 1.37 (95% CI = 1.13-1.66) in the blood transfusion cohort.
Incidence and HRs of Dementia Comparison Different Type Blood Transfusion and Matched Cohorts
Additionally, we analyzed the incidence and HR of dementia according to the different types of blood transfusions ( The results indicated that at the end of the follow-up period, the cumulative incidence of dementia was higher in the blood transfusion cohort than in the matched cohort (log-rank test, p < 0.001) (Figure 1) . The risk of dementia fell over time but persisted through the follow-up period ( Table 5 
Relationship Between the Frequency of Blood Transfusion and the Risk of Dementia Development
The risk of dementia development was higher in patients presenting with 1, 2 or ≥3 blood transfusions compared with those in the matched cohort (p for trend <0.001) ( Table 6 ).
DISCUSSION
This study showed an association between blood transfusions and the risk of dementia. There are several possible explanations for our findings. First, transfusion might cause dysregulated iron metabolism in transfused patients. Lei et al. have also showed that Tau deficiency could induce parkinsonism with dementia by impairing the Amyloid precursor proteinmediated iron export (20) . Duce et al. have found that ironexport ferroxidase activity of the β-amyloid precursor protein undergoes interference and is inhibited in AD (21) . Transfusion has been linked with dysregulated iron metabolism in chronic transfused patients (14) and iron has been implicated in the pathology of many neurodegenerative diseases (36) (37) (38) (39) . Therefore, the dysregulated metabolism of iron as a result of transfusion might assist with the development of dementia in transfused patients. Second, transfusion-related inflammation might be involved in the pathogenesis of dementia. Patients who require transfusion are those with many comorbidities including diabetes mellitus, hypertension, chronic kidney disease, and stroke etc. It has been reported that transfusion could evoke inflammation and associated inflammatory cytokines. Cognasse et al. stated that microparticles originating from platelets, leukocytes, erythrocytes, and endothelial cells can trigger a pro-inflammatory message during transfusion (40) . Chronic inflammation has been linked to neurodegenerative changes in the brain and the risks of dementia (41-44). Engelhart et al. also reported that increased levels of the plasma protein are associated with risks of dementia (45) . Therefore, (50, 51) . However, since information about dementia of donors was unavailable, our study could not establish a direct relationship that neurodegenerative disease could be transmitted via blood transfusion. The mechanism remains unknown and future laboratory studied are needed to clarify the pathway. Although both our study and the Edgren et al. study (33) investigated whether transfusion was associated with the risk of neurodegenerative disease, the two studies are not really comparable because the study designs were different. Several distinct differences in the present study and the Edgren et al. study should be mentioned here for future considerations and studies (33) . First, Edgren et al. (33) reported that the risk of neurodegenerative diseases in recipients of blood transfusions from donors with a record of neurodegenerative disease was insignificant, while our study was an external comparison of the risk of neurodegenerative disease between recipients of blood from unknown donors and persons with no history of blood transfusion. Second, we have matched considerable dementia-associated comorbidities and medications, while Edgren et al. (33) considered age, gender, country, and diseases of donors. Chasse et al. investigated the association between blood donor age and sex with recipient survival (52). Chasse et al. considered many confounders in their study (52) . From the study design of Chaase et al. (52) , it is reasonable to surmise that confounders are critically important when investigating the consequences of blood transfusion.
Our data also showed that the risk of dementia was significantly higher, especially within 3 years following blood transfusion. Patients who require blood transfusion require more medical visits following the blood transfusion, thus providing more chances of finding dementia. Another supposed reason would be the competing risk that patients who require blood transfusions might have a shortened survival duration; thus, the risk of dementia seems decreased with years following transfusion.
Several limitations of this study should be mentioned. First, information on the apolipoprotein E genotype and the family history of each individual is unavailable. The influence of genetics could therefore not be evaluated in this study. Second, data on homocysteine levels (30), cholesterol levels, blood glucose levels, blood pressure, body mass index, smoking habits, alcohol consumption, sun exposure, and education levels, which are potential confounding factors of dementia, are unavailable in the NHIRD. However, to minimize the possible bias, we matched sex; occupation; associated comorbidities, including obesity, hypertension, diabetes, hyperlipidemia, and CKD (which is associated with a high homocysteine level); and medication associated with dementia. It should be noted that although we have utilized occupation as a proxy for educational level, occupation is not directly tightly associated with education level. Therefore, our study results showed that those with white collar jobs had a lower risk of dementia, which could not absolutely be caused by the higher level of education. Third, this study was conducted with registry data while dementia is often missed in registry data. Therefore, the events and risks of dementia might be underestimated. Fourth, the possibility of confounding through the indication of blood transfusion should also be considered. We have added gastrointestinal bleeding and surgery as the two circumstances that most warrant transfusion as variables to lessen the possible baseline bias. Fifth, information of variables including APOE, hippocampal volume or global atrophy or amnestic phenotype was unavailable in this study, which could potentially cause bias. Sixth, this is an external study and since those who need a transfusion might not be as likely as those who did not need a transfusion, a potential baseline bias could exist. However, we have done propensity matching to minimize this bias. Finally, whether blood donors had neurodegenerative diseases was unknown in this study. The medical follow up was short, which might not allow for enough time to assess for the incidence of AD or dementia cases in the young patient category. Further, each individual has a different post-transduction period and the number of doctor visits, in order to monitor his/her health status, was another limitation. The direct relationship between neurodegenerative diseases and blood transfusions could not be established in this study. In conclusion, the results of the current study indicate that blood transfusions are associated with risks of dementia or AD. Transfusion is associated with the risk of dementia, regardless of transfusion frequency. Additional research is required to elucidate the biological mechanism underlying this association. This study promotes clinical alertness relating to the safety of blood transfusions, beyond previously known issues of hepatitis and HIV. 
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